Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16375315 | 0.92 | EGFR (0.41) | EGFRERBB2KDM4ESTAT3KMT2A | |
| SCHEMBL16375308 | 0.85 | EGFR (0.51) | EGFRERBB2KDM4EKMT2AMEN1 | |
| SCHEMBL15607901 | 0.81 | EGFR (0.35) | EGFRERBB2KDM4EKMT2AMEN1 | |
| SCHEMBL16375313 | 0.80 | EGFR (0.34) | EGFRERBB2KDM4EKMT2AMEN1 | |
| SCHEMBL15607955 | 0.79 | KMT2A (0.35) | EGFRERBB2STAT3KMT2AMEN1 | |
| SCHEMBL15607824 | 0.79 | MEN1 (0.37) | EGFRERBB2KDM4EKMT2AMEN1 | |
| SCHEMBL16375307 | 0.78 | EGFR (0.49) | EGFRERBB2KDM4EKMT2AMEN1 | |
| SCHEMBL15607944 | 0.77 | MAPT (0.38) | EGFRERBB2KDM4ESTAT3KMT2A | |
| SCHEMBL16375030 | 0.77 | PKM (0.41) | EGFRERBB2KDM4EKMT2AMEN1 | |
| SCHEMBL16375036 | 0.77 | F2 (0.39) | EGFRERBB2KDM4ESTAT3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | EGFR 1866/4885ERBB2 1218/4885KDM4E 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.